Patents by Inventor Rigel Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein Kinase C Inhibitors and Uses Thereof
    Publication number: 20130331374
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: April 4, 2013
    Publication date: December 12, 2013
    Inventor: Rigel Pharmaceuticals, Inc.
  • Prodrugs of 2,4-Pyrimidinediamine Compounds and Their Uses
    Publication number: 20130310341
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: April 12, 2013
    Publication date: November 21, 2013
    Inventor: Rigel Pharmaceuticals, Inc.
  • Multiparameter FACS Assays to Detect Alterations in Cellular Parameters and to Screen Small Molecule Libraries
    Publication number: 20130310278
    Abstract: The invention relates to novel methods of detecting alterations in cell cycle regulation in a cell or a cell population and screening for agents capable of modulating cell cycle regulation through the use of multiparameter assays and a fluorescence-activated cell sorter (FACS) machine.
    Type: Application
    Filed: November 7, 2012
    Publication date: November 21, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • Cycloalkyl Substituted Pyrimidinediamine Compounds And Their Uses
    Publication number: 20130210814
    Abstract: The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.
    Type: Application
    Filed: February 1, 2013
    Publication date: August 15, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • Protein Kinase C Inhibitors and Uses Thereof
    Publication number: 20130210810
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: December 18, 2012
    Publication date: August 15, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: Rigel Pharmaceuticals, Inc.
  • AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME
    Publication number: 20130203987
    Abstract: Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by “B”, T, R3, R4, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.
    Type: Application
    Filed: March 13, 2013
    Publication date: August 8, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • Wet Granulation Using a Water Sequestering Agent
    Publication number: 20130189359
    Abstract: Disclosed are tablets comprising hydrolytically stable formulations of (6-(5-fluoro-2-(3,4,5-trimethoxyphenylamino)pyrimidin-4-ylamino)-2,2-dimethyl-3-oxo-2H-pyrido[3,2-b][1,4]oxazin-4(3H)-yl)methyl phosphate disodium salt (Compound 1) prepared by a wet granulation process.
    Type: Application
    Filed: January 10, 2013
    Publication date: July 25, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • TOPICAL FORMULATION FOR ADMINISTERING A COMPOUND
    Publication number: 20130150334
    Abstract: Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.
    Type: Application
    Filed: December 6, 2012
    Publication date: June 13, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
    Publication number: 20130150349
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Application
    Filed: February 5, 2013
    Publication date: June 13, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses
    Publication number: 20130150329
    Abstract: The present disclosure provides biologically active 2,4-pyrimidinediamine compounds of formulae (I)-(III): and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications.
    Type: Application
    Filed: February 5, 2013
    Publication date: June 13, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • Protein Kinase C Inhibitors and Uses Thereof
    Publication number: 20130143875
    Abstract: This disclosure concerns compounds which are useful as inhibitors of protein kinase C (PKC) and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC. This disclosure also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Application
    Filed: February 6, 2013
    Publication date: June 6, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20130142807
    Abstract: The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.
    Type: Application
    Filed: January 25, 2013
    Publication date: June 6, 2013
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventor: Rigel Pharmaceuticals, Inc.
  • POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
    Publication number: 20130109695
    Abstract: Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Application
    Filed: December 21, 2012
    Publication date: May 2, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • METHOD AND DEVICE FOR ADMINISTERING XINAFOATE SALT OF N4-(2,2-DIFLUORO-4H-BENZO [1,4]OXAZIN-3-ONE)-6-YL]-5-FLUORO-N2-[3- (METHYLAMINOCARBONYLMETHYLENEOXY) PHENYL]2,4-PYRIMIDINEDIAMINE
    Publication number: 20130102596
    Abstract: Disclosed embodiments concern a device for administering a xinafoate salt of N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-N2-[3-(methylaminocarbonylmethyleneoxy)phenyl]-2,4-pyrimidinediamine, or compositions thereof, and a method for making and using the device. Particular disclosed embodiments concern formulating the xinafoate salt for administration via the device.
    Type: Application
    Filed: October 19, 2012
    Publication date: April 25, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS
    Publication number: 20130090330
    Abstract: N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.
    Type: Application
    Filed: October 4, 2012
    Publication date: April 11, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20130090310
    Abstract: Disclosed are compounds of formula I, compositions containing them, and methods of use for the compounds and compositions in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK 2 and JAK3, are therapeutically useful. Also disclosed are methods of making the compounds.
    Type: Application
    Filed: November 26, 2012
    Publication date: April 11, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: RIGEL PHARMACEUTICALS, INC.
  • Synthesis of 2,4-Pyrimidinediamines
    Publication number: 20130018185
    Abstract: Disclosed herein are methods for synthesizing 2,4-pyrimidinediamines as well as intermediates used therein.
    Type: Application
    Filed: September 24, 2012
    Publication date: January 17, 2013
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventor: Rigel Pharmaceuticals, Inc.